234 related articles for article (PubMed ID: 22042695)
1. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.
Björkman S; Oh M; Spotts G; Schroth P; Fritsch S; Ewenstein BM; Casey K; Fischer K; Blanchette VS; Collins PW
Blood; 2012 Jan; 119(2):612-8. PubMed ID: 22042695
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
[TBL] [Abstract][Full Text] [Related]
4. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
Delavenne X; Dargaud Y; Ollier E; Négrier C
Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.
Garmann D; McLeay S; Shah A; Vis P; Maas Enriquez M; Ploeger BA
Haemophilia; 2017 Jul; 23(4):528-537. PubMed ID: 28220555
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
10. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
11. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
[TBL] [Abstract][Full Text] [Related]
12. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
[TBL] [Abstract][Full Text] [Related]
13. Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.
Garcia-Martínez I; Borràs N; Martorell M; Parra R; Altisent C; Ramírez L; Álvarez-Román MT; Nuñez R; Megias-Vericat JE; Corrales I; Alonso S; Vidal F
Thromb Haemost; 2020 Oct; 120(10):1395-1406. PubMed ID: 32726853
[TBL] [Abstract][Full Text] [Related]
14. Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
Lunghi B; Bernardi F; Martinelli N; Frusconi S; Branchini A; Linari S; Marchetti G; Castaman G; Morfini M
J Thromb Haemost; 2019 Aug; 17(8):1288-1296. PubMed ID: 31055871
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.
Morfini M; Marchesini E; Paladino E; Santoro C; Zanon E; Iorio A
Haemophilia; 2015 Mar; 21(2):204-209. PubMed ID: 25274155
[TBL] [Abstract][Full Text] [Related]
16. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
[TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
[TBL] [Abstract][Full Text] [Related]
20. A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
Blanchette VS; Zunino L; Grassmann V; Barnes C; Carcao MD; Curtin J; Jackson S; Khoo L; Komrska V; Lillicrap D; Morfini M; Romanova G; Stephens D; Zapotocka E; Rand ML; Blatny J
Thromb Haemost; 2021 Oct; 121(10):1326-1336. PubMed ID: 33506480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]